Clinical Trials for CIDP

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which the immune system attacks the protective covering around nerve fibers, leading to weakness, numbness, and impaired mobility. It is treatable, but treatment can be expensive -- and insurance denials for IVIG and other therapies are a real and frustrating problem for many people with CIDP.

Clinical trials are actively studying new and improved treatments for CIDP. Whether you are newly diagnosed, not responding adequately to current therapy, or facing an insurance barrier, trials may be worth exploring.

According to the GBS|CIDP Foundation International, CIDP affects approximately 1 to 9 people per 100,000, making it relatively rare but well-represented in clinical research.

What Types of Trials Are Available?

CIDP trial research spans multiple approaches:

FcRn inhibitor trials are among the most active in CIDP right now. These drugs reduce levels of IgG antibodies (including the harmful ones attacking your nerves) and represent a newer class of treatment being studied in Phase 2 and Phase 3 trials. Subcutaneous immunoglobulin (SCIG) trials are studying home-based alternatives to intravenous IVIG infusions, which are burdensome for many people. These trials often enroll people who are already stable on IVIG. Early-phase immunotherapy trials are exploring more targeted immune modulation for people whose CIDP does not respond to standard treatments.

Search ClinicalTrials.gov for currently recruiting trials.

Am I Eligible?

Common eligibility factors for CIDP trials include:

- Confirmed diagnosis of CIDP (often requiring nerve conduction study results and clinical criteria)

- Active or inadequately controlled disease, or demonstrated prior response to IVIG/SCIG

- Specific antibody testing (some trials look for anti-nodal/paranodal antibodies)

- No recent enrollment in other interventional studies

Some trials specifically enroll IVIG-dependent participants. Others look for people who have never been treated, or whose disease is progressing despite treatment.

Your neurologist's involvement is essential here. The diagnostic nuances of CIDP significantly affect which trials you might be eligible for. Talk to your doctor before making any decisions about your treatment.

What If My Insurance Denied My Medication?

IVIG and subcutaneous immunoglobulin therapies like Hizentra, Privigen, and Gamunex-C are routinely denied or restricted by insurance, even when they are medically necessary. If your neurologist has prescribed immunoglobulin therapy and your insurer has said no, that denial is not the final word.

You can appeal, request a peer-to-peer review between your neurologist and the insurance company's medical director, and simultaneously explore trial options that might provide access to similar or newer treatments.

Ellen can help you organize your denial, understand your appeal rights, and identify active CIDP trials.

Ellen can help you figure out your next step. Start with Ellen →

Frequently Asked Questions

Are clinical trials for CIDP free?

In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.

How do I find CIDP trials near me?

The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.

Can I join a trial after being denied Privigen or Hizentra?

Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Privigen or Hizentra or similar medications.